A Phase 1 study of BNT314 with or without pembrolizumab in solid tumors
Active, Not Recruiting Phase 1 NCT06150183
Study Description
A study to test the safety and preliminary efficacy of a new cancer drug (BNT314) alone or combined with another cancer drug (pembrolizumab) in patients with different types of solid tumors
Study Details
- Registry ID:
- NCT06150183
- Conditions:
- Advanced Malignant Solid Tumor
- Phase:
- Phase 1
- Target Enrollment:
- 41 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (15 sites)
-
Hospital Fund. Jiménez Dia
Madrid, Spain -
Hospital HM Univ. Sanchinarro, Ensayos START
Madrid, Spain -
Hospital Quironsalud Barcelona (NEXT Barcelona)
Barcelona, Spain -
Clinica Universidad de Navarra
Pamplona, Spain -
CHU de Liège
Liege, Belgium -
GZA Ziekenhuizen
Antwerpen, Belgium -
GZA Ziekenhuizen
Antwerp, Belgium -
Royal Marsden Hospital - London
London, United Kingdom -
The Christie Hospital
Manchester, United Kingdom -
Northern Centre for Cancer Care
Newcastle, United Kingdom -
Rigshospitalet
Copenhagen, Denmark -
Carolina BioOncology Institute, LLC
Huntersville, North Carolina, United States -
Cleveland Clinic
Cleveland, Ohio, United States -
START Midwest
Grand Rapids, Michigan, United States -
National Cancer Center Hospital East
Kashiwanoha, Japan
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.